Efficacia e tollerabilita a lungo termine del vigabatrin come terapia aggiuntiva nelle epilessie farmacoresistenti dell'adulto

Translated title of the contribution: Long term efficacy and tolerability of Vigabatrin as add-on treatment in adult refractory epilepsy

A. Tartara, R. Manni, C. Galimberti, I. Sartori, R. Murelli, E. Marchioni, E. Perucca

Research output: Contribution to journalArticlepeer-review

Abstract

After a mean follow-up of 34 months (range 6-161 months) 52% of 162 patients with refractory epilepsy (mostly with partial seizures) continue on add-on Vigabatrin treatment. Ten percent are seizure-free and an additional 12% achieved a greater than 75% reduction in seizures frequency. None of the patients with generalized epilepsies responded. Only 11% discontinued treatment because of adverse effects, usually within the first 6 months.

Translated title of the contributionLong term efficacy and tolerability of Vigabatrin as add-on treatment in adult refractory epilepsy
Original languageItalian
Pages (from-to)23-25
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number99 SUPPL. 1
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Long term efficacy and tolerability of Vigabatrin as add-on treatment in adult refractory epilepsy'. Together they form a unique fingerprint.

Cite this